Buto has a unique therapeutic focus, to block inflammation of the innate immune system that drives both Alzheimer's Disease (AD) and fibrosis.
Our molecules ameliorate AD in two mouse models, and benefit human lung fibrosis and lung and liver fibrosis in multiple mouse models.
Buto's molecules uniquely inhibit the Shc protein and pathway. Shc expression and activity rise in innate immune cells in AD and fibrosis.
In AD, repetitive injury by A-beta amyloid inflames brain microglia, causing memory loss. In fibrosis, repetitive injury inflames tissue macrophages, causing fibrosis.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.